Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Incyte CorporationNASDAQ: INCY

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 investing cash flow of $51.79M (cash outflow) rose 174.4% year over year, behind the +23174.4% change in trailing-twelve-month investing cash flow. Sequentially, it fell 41.3% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Investing cash flow amounted to 2.0% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +174.4% toward the trailing-twelve-month pace of +23174.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$51.79M-41.3% QoQ
Last fiscal yearDec 2025
-$102.61M-165.1% YoY
LTMJun 2026
-$224.83M+23174.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+174.4%——
1 year-165.1%——
3-year CAGR+9.3%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(102.61M) USD
Year-over-year change
-165.1%

Investing Cash Flow vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 investing cash flow of $224.83M is the 4th largest of the 11 companies compared; the peer median is $12.82M.
  • Its year-over-year change of +23174.4% is the highest of 9, against a peer median of +32.2%.
  • Investing cash flow amounts to 3.9% of revenue for INCY, versus a peer median of 16.7%.
INCY Competitors Peer median
Investing Cash Flow for INCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$5.64B —+26.9%136.5%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$704.2M +5.1%-45.0%4.5%
LEGNLegend Biotech CorporationLTM Sep 2026$226.82M +1455.9%—16.7%
INCYIncyte CorporationLTM Jun 2026$224.83M +23174.4%+9.3%3.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$175.6M +256.1%-10.3%—
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$144.78M +59.3%—49.8%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$104.47M -32.9%——
EXELExelixis, Inc.LTM Jul 2026$93.01M +840.9%—3.8%
VSTMVerastem, Inc.LTM Mar 2026$25.64M -188.4%—51.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$1.1M -83.6%+75.8%0.2%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ———
Peer median (excluding INCY) $12.82M+32.2%+8.3%16.7%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income948.58M340.66M597.6M32.62M1.29B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
Deferred Income Tax(465.6M)57.09M(158.9M)(85.55M)247.69M
Stock-Based Compensation183.01M188.42M215.89M266.06M249.35M
Change in Working Capital(14.57M)198.81M(248.65M)138.24M(527.16M)
Accounts Receivables(134.31M)(28.58M)(98.68M)(111.59M)(170.77M)
Inventory(20.97M)(67.5M)(170.15M)(127.63M)(58.51M)
Accounts Payables73.34M105.44M(167.95M)88.16M6.56M
Other Working Capital67.36M189.46M188.12M289.3M(304.44M)
Other Non-Cash Items40.23M117.11M7.89M(105.28M)63.69M
Operating Cash Flow749.49M969.94M496.49M335.34M1.41B
Capital Expenditures(181.01M)(77.83M)(32.49M)(86.26M)(58.87M)
Acquisitions (Net)00000
Purchases of Investments(268.68M)(79.86M)(466.02M)(258.37M)(303.38M)
Sales of Investments241.98M79.15M305.83M516.05M284.64M
Other Investing Activities00000
Investing Cash Flow(207.7M)(78.54M)(207.68M)157.52M(102.61M)
Debt Repayment(2.42M)(2.86M)(3.36M)(3.8M)(4.54M)
Common Stock Issued58.63M61.12M35.84M49.3M221.76M
Common Stock Repurchased000(2B)(19.1M)
Dividends Paid00000
Other Financing Activities(50.03M)(59.05M)(52.51M)(62.26M)(97.08M)
Financing Cash Flow6.18M(794K)(20.03M)(2.02B)101.04M
Effect of Forex Changes(3.53M)3.38M(6.82M)3.15M(1.94M)
Net Change in Cash544.43M893.98M261.95M(1.53B)1.41B
Free Cash Flow568.48M892.11M464M249.07M1.35B

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.